Frequently Asked Questions

1. What is Kesimpta, and how does it work?

   Kesimpta is a prescription medication specifically approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is a monoclonal antibody that targets B-cells, which are believed to play a critical role in the progression of MS. By binding to the CD20 protein on these cells, Kesimpta decreases their activity, helping to reduce inflammation and prevent the immune system from attacking the nerves in the brain and spinal cord. This process helps to slow the progression of MS and reduce the frequency of relapses.

2. How is Kesimpta administered?

   Kesimpta is administered as a subcutaneous injection, meaning it’s injected under the skin. Patients can use a pre-filled Sensoready pen or pre-filled syringe to self-administer the medication at home. The initial dosing involves weekly injections for the first three weeks (Weeks 0, 1, and 2), followed by monthly injections starting at Week 4. This dosing schedule helps to establish the medication’s effects quickly and maintain them over time.

3. What are the most common side effects of Kesimpta?

   Common side effects of Kesimpta include upper respiratory tract infections (such as sore throat and runny nose), headache, injection site reactions (redness, swelling, itching, or pain), fever, chills, muscle aches, and fatigue. These side effects are usually mild to moderate and tend to decrease after the first few injections. However, if they persist or worsen, it is advisable to contact a healthcare provider.

4. Is Kesimpta an immunosuppressant?

   Yes, Kesimpta acts as an immunosuppressant by reducing the activity of the immune system, specifically targeting B-cells. While this mechanism helps control MS symptoms, it also increases the risk of infections. Patients should avoid contact with people who have contagious infections and discuss their vaccination history with healthcare providers before starting treatment.

5. How does Kesimpta compare to other MS treatments like Ocrevus?

   Kesimpta and Ocrevus are both used to treat certain forms of MS, but they differ in administration and specific indications. Kesimpta is a subcutaneous injection, while Ocrevus is given as an intravenous infusion. Some studies suggest Kesimpta may offer more convenience due to its at-home administration, but direct clinical comparisons are limited. Patients should discuss with their doctors to determine the best option based on their specific condition and lifestyle.

6. What precautions should be taken before starting Kesimpta?

   Before starting Kesimpta, patients should be screened for hepatitis B and other infections. Vaccinations should be updated, and any live or live-attenuated vaccines should be administered at least four weeks before treatment begins. Pregnant or breastfeeding women should consult their healthcare providers to understand the potential risks, as the effects of Kesimpta on an unborn child or during lactation are not fully understood.

7. How should Kesimpta be stored?

   Kesimpta should be stored in a refrigerator at temperatures between 36°F to 46°F (2°C to 8°C) and kept in its original packaging to protect it from light. The medication should not be frozen or shaken. If necessary, Kesimpta can be stored at room temperature for up to seven days, but it must be used or discarded after this period.

8. What should patients do if they miss a dose of Kesimpta?

   If a patient misses a dose during the initial weekly dosing phase, they should contact their healthcare provider for guidance. For missed monthly doses, the patient should administer the missed dose as soon as possible without waiting for the next scheduled injection, then continue with the regular dosing schedule. Consistency in dosing helps maintain the effectiveness of the treatment.

9. Can patients drink alcohol while taking Kesimpta?

   While there are no specific interactions between Kesimpta and alcohol, patients are advised to limit alcohol consumption. Both MS symptoms and alcohol can affect coordination and cognitive functions, so moderation is recommended. Patients should discuss their alcohol use with their healthcare provider to ensure it aligns with their treatment plan.

10. How long does it take for Kesimpta to show effects?

    Kesimpta begins to work within a week of starting treatment, as it starts to lower B-cell levels in the body. Clinical studies have shown that significant reductions in MS relapses and disease progression can be observed as early as three months into treatment. However, individual responses may vary, and ongoing monitoring by healthcare providers is essential to evaluate the treatment’s effectiveness.